ProCE Banner Activity

Ponatinib vs AlloSCT in CML or Ph+ ALL With T315I Mutation

Slideset Download
Conference Coverage
Retrospective observational data indicated that ponatinib achieved significantly longer OS in T315I+ CP-CML vs alloSCT.

Released: December 12, 2015

Expiration: December 10, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen